Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Zhen Wang, MD
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04258462CT.gov Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Renal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pyruvate (this asset) | Zhen Wang, MD | P2 | CCC · 51 |
| Nivolumab | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P4 | BBB |
| Cabozantinib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P4 | BB |
| Pembrolizumab | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P4 | BB |
| Ipilimumab | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P4 | BB |
| Ropivacaine | Wake Forest University Health Sciences | P3 | B |
| Epinephrine | Wake Forest University Health Sciences | P3 | B |
| Marcaine | Wake Forest University Health Sciences | P3 | B |
| Lenvatinib | Gustave Roussy, Cancer Campus, Grand Paris | P3 | B |
+42 more in the Renal Carcinoma cohort
Other indications for Pyruvate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P2 | B · 56 |
| Prostate Carcinoma | — | P2 | B · 56 |
| Relapsing-Remitting Multiple Sclerosis | — | P2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- NivolumabFondazione Policlinico Universitario Agostino Gemelli IRCCSBBB
- CabozantinibFondazione Policlinico Universitario Agostino Gemelli IRCCSBB
- PembrolizumabFondazione Policlinico Universitario Agostino Gemelli IRCCSBB
- IpilimumabFondazione Policlinico Universitario Agostino Gemelli IRCCSBB
- RopivacaineWake Forest University Health SciencesB
Citation
Floatz Terminal. Pyruvate in Renal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pyruvate-renal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →